

M. Melnikov <sup>1-3</sup> (main author), A. Sviridova <sup>1</sup>, M. Pashenkov <sup>3</sup>, A. Boyko <sup>1,2</sup>.

<sup>1</sup> Federal Center of Brain research and Neurotechnology of the Federal Medical Biological Agency of Russia, Department of Neuroimmunology, Moscow, Russia

<sup>2</sup> Pirogov Russian National Research Medical University, Department of Neurology, Neurosurgery and Medical Genetics, Moscow, Russia

<sup>3</sup> National Research Center Institute of Immunology of the Federal Medical Biological Agency of Russia, Laboratory of Clinical Immunology, Moscow, Russia

**Introduction:** Dopamine may participate in multiple sclerosis (MS) pathogenesis by modulating immune cell activity and cytokine production. This study aimed to clarify the effect of dopamine on Th17-cells, which plays a critical role in MS pathogenesis.

**Methods:** Forty patients with relapsing-remitting MS during clinical remission and twenty-five healthy subjects were examined. The concentrations of dopamine in blood plasma and culture supernatants were measured by high-performance liquid chromatography. The percentage of blood Th17-cells was determined by flow cytometry (CD4<sup>+</sup>CD161<sup>+</sup>). To assess the effect of dopamine on Th17-cells, purified CD4<sup>+</sup>-T-cells were cultured in the presence of dopamine (10<sup>-5</sup> M) and stimulated with anti-CD3/anti-CD28-antibodies. The levels of IL-17, IFN- $\gamma$ , and GM-CSF in culture supernatants were assessed by ELISA. To study the involvement of dopaminergic receptors in dopamine-mediated immunomodulation, some samples of CD4<sup>+</sup>-T-cells were pre-incubated with antagonist of D<sub>1</sub>- or D<sub>2</sub>-dopaminergic receptors, whereafter dopamine and anti-CD3/anti-CD28-antibodies were added to the cultures. In some experiments, CD4<sup>+</sup>-T-cells were pre-incubated with antagonist of D<sub>1</sub>- or D<sub>2</sub>-dopaminergic receptors (both at 10<sup>-5</sup> M) and activated by anti-CD3/anti-CD28-antibodies.

**Results:** The concentrations of dopamine in plasma and culture supernatants were not different between the groups. The percentages of Th17-cells, as well as the production of cytokines, were also comparable. Dopamine suppressed cytokine production in both groups ( $p < 0.0001$ ) without affecting on cell viability and proliferative response. Blockade of D<sub>1</sub>-receptors enhanced the inhibitory effect of dopamine on cytokine production in both groups ( $p < 0.05$ ), while blockade of D<sub>2</sub>-receptors decreased the inhibitory effect of dopamine in both groups ( $p < 0.05$ ). The blockade of D<sub>1</sub>-receptors suppressed cytokine production in both groups ( $p < 0.01$ ).

**Conclusion:** These data suggest the inhibitory effect of dopamine on Th17-cells in MS, which could be mediated by the D<sub>2</sub>-dopaminergic receptors.